Eur J Cardiothorac Surg.2017;52(3):522-528. [4] Isaka T, Ito H, Nakayama H, et al. Efficacy of platinum-based adjuvant chemotherapy onprognosis of pathological stage II/III lung adenocarcinoma based on EGFR mutation status:a propensity scor...
[8] Suda K, Mitsudomi T, Shintani Y, et al. Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Ann Thorac Surg. 2021 Jan;111(1):269-276. doi: 10.1016/j.athoracsur....
Douillard JY,et al., Relationship Between EGFR Expression, EGFR Mutation Status, and the Ef cacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced NonCSmall-Cell Lung Cancer,J Thorac Oncol. 2014 May;9(5):717-24.
This study had several limitations. First, we could not compare the results of theEGFRmutation status in the pleural effusion fluid to the mutation status in tumour tissue. Forty of the 43 patients enrolled were cytologically diagnosed as having NSCLC from pleural effusion fluid specimens. As the...
ofEGFRmutation,wehavereturnedtotherationalthinkingfrom theinitialdiscoveryofsurprise,enthusiasmfordetectionand reporting:isthereanyheterogeneityintheEGFRmutationin thesametumortissue?DoestheEGFRmutationinprimaryand metastaticlesionschange?IsthemutationstatusofEGFR ...
An end-to-end deep learning model was proposed to predict the EGFR mutation status by CT scanning.By training in 14 926 CT images, the deep learning model achieved encouraging predictive performance in both the primary cohort (n=603; AUC 0.85, 95% CI 0.83-0.88) and the independent ...
EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery - International Journal of Radiation Oncology • Biology • Physics...
1. EGFR mutation subtypes and response to immunecheckpoint blockade treatment in non-small cell lung cancer.Ann Oncol.2019 May 14. pii: mdz141.2. Tumor immune microenvironment and nivolumab efficacyin EGFR mutation-positive non-small-cell lung cancer based on T790M statusafter disease progression ...
Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for...
Comparative scRNA-seq analysis reveals immune cell subsets differentially accumulated between EGFR-mutant and wild-type tumors in NSCLC To compare the cellular landscape between two different molecular subtypes of lung cancer based on theEGFRmutation status, we prepared tumor specimens surgically resected ...